RecruitingPhase 3NCT04161053
Efficacy and Safety of Nitazoxanide in Preventing Recurrence of Hepatic Encephalopathy
Clinical Study Evaluating the Efficacy and Safety of Nitazoxanide in Preventing Recurrence of Hepatic Encephalopathy
Sponsor
Tanta University
Enrollment
60 participants
Start Date
Nov 1, 2018
Study Type
INTERVENTIONAL
Conditions
Summary
Efficacy and Safety of Nitazoxanide in preventing recurrence of Hepatic Encephalopathy.
Eligibility
Min Age: 20 YearsMax Age: 65 Years
Inclusion Criteria2
- Cirrhotic patient with at least one previous episode of hepatic encephalopathy.
- Adult Patients aging from 20 to 65 years old
Exclusion Criteria3
- Active GIT bleeding.
- Major psychiatric illness (psychosis \& epilepsy).
- Renal insufficiency (S.Cr 2mg/dl).
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGRifaximin
Rifaximin 550 mg twice daily for 6 months
DRUGNitazoxanide
Nitazoxanide 500 mg twice daily for 6 months
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04161053
Related Trials
Apixaban-PK Trial: Preventing Portal Hypertension Complications in Cirrhosis
NCT075213321 location
Hepatic Encephalopathy and Albumin Lasting Cognitive Improvement
NCT060521761 location
TReatment for ImmUne Mediated PathopHysiology
NCT0486222124 locations
The Liver Cirrhosis Cognitive Decline Scale (LiCCoS)
NCT074180081 location
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
NCT064253802 locations